Girotto M, Comoglio C, Donegani E, Di Summa M
Cattedra di Cardiochirurgia, Università degli Studi di Torino.
Riv Eur Sci Med Farmacol. 1993 Jan-Feb;15(1):43-6.
A total of 200 patients (131 males and 69 females), scheduled for cardiovascular surgery were randomly assigned to receive either sulbactam/ampicillin 1 g IV of cefuroxime 2 g IV before the surgical incision and then, postoperatively, 8-hourly x 3 days. There were five failure of prophylaxis (all in the cefuroxime group): 3 sternal incision abscesses (1 Pseudomonas aeruginosa and 2 Staphylococcus epidermidis), one urinary tract infection (Staphylococcus aureus) and one Micrococcus pneumoniae. Tolerance to both antibiotics was excellent. In our sample of patients, the efficacy and safety of sulbactam/ampicillin were not different from those of cefuroxime in prophylaxis in cardiovascular surgery.
共有200例计划进行心血管手术的患者(男性131例,女性69例),被随机分配在手术切口前静脉注射1克舒巴坦/氨苄西林或2克头孢呋辛,术后每8小时一次,共3天。有5例预防失败(均在头孢呋辛组):3例胸骨切口脓肿(1例铜绿假单胞菌和2例表皮葡萄球菌)、1例尿路感染(金黄色葡萄球菌)和1例肺炎微球菌。两种抗生素的耐受性都很好。在我们的患者样本中,舒巴坦/氨苄西林在心血管手术预防中的疗效和安全性与头孢呋辛无异。